Novavax

GPTKB entity

Statements (62)

Predicate	Object
gptkbp:instance_of	gptkb:biotechnology
gptkbp:ceo	gptkb:Stanley_C._Erck
gptkbp:clinical_trial	Phase 3 trials Phase 1 trials Phase 2 trials
gptkbp:collaboration	gptkb:CEPI Institute of Health Research
gptkbp:focus	vaccine development
gptkbp:founded	gptkb:1987
gptkbp:funding	gptkb:U._S._government
gptkbp:headquarters	gptkb:Gaithersburg,_Maryland
https://www.w3.org/2000/01/rdf-schema#label	Novavax
gptkbp:is_vulnerable_to	gptkb:Zika_vaccine gptkb:Ebola_vaccine gptkb:vaccine global health live attenuated vaccine DNA vaccine influenza vaccine malaria vaccine HIV vaccine inactivated virus vaccine viral vector vaccine subunit vaccine protein subunit vaccine Nipah virus vaccine RSV vaccine chikungunya vaccine dengue vaccine tuberculosis vaccine MERS-Co V vaccine SARS-Co V vaccine West Nile virus vaccine
gptkbp:notable_products	gptkb:NVX-Co_V2373
gptkbp:partnership	gptkb:Bill_&_Melinda_Gates_Foundation gptkb:Gavi,_the_Vaccine_Alliance
gptkbp:publicly_traded	gptkb:NASDAQ
gptkbp:research_focus	infectious diseases
gptkbp:vaccine_administration	two doses
gptkbp:vaccine_approval	gptkb:WHO_Emergency_Use_Listing Emergency Use Authorization
gptkbp:vaccine_candidate	COVID-19 vaccine candidate
gptkbp:vaccine_distribution	gptkb:CORBA global distribution
gptkbp:vaccine_effectiveness	against variants
gptkbp:vaccine_efficacy	90% in clinical trials
gptkbp:vaccine_investment	significant investment
gptkbp:vaccine_partnership	gptkb:Astra_Zeneca gptkb:Serum_Institute_of_India gptkb:U._S._National_Institutes_of_Health gptkb:U._S._Department_of_Defense
gptkbp:vaccine_platform	gptkb:Matrix-M_adjuvant
gptkbp:vaccine_research	collaborative research ongoing research
gptkbp:vaccine_safety	monitored in trials
gptkbp:vaccine_storage	2-8 degrees Celsius
gptkbp:vaccine_technology	recombinant nanoparticle technology adjuvanted protein subunit
gptkbp:bfsParent	gptkb:Takeda_Pharmaceuticals_Europe_Ltd. gptkb:Emergent_Bio_Solutions gptkb:Takeda_Pharmaceutical_Company_Limited
gptkbp:bfsLayer	6